New pill shows promise for tough lung cancer

NCT ID NCT07231068

Recruiting now Disease control Sponsor: Henan Genuine Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new oral drug called dositinib in people with advanced non-small cell lung cancer that has a specific EGFR mutation. The trial has two parts: first, finding the safest dose, then testing that dose in a larger group. Researchers will monitor side effects, how the drug moves through the body, and whether it shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dositinib mesylate tablets (90-1408)
What this could lead to: If successful, this could provide a new targeted treatment option for people with advanced EGFR-mutant lung cancer.
What could go wrong: This is an early-phase trial with small numbers, so safety and effectiveness are not yet proven. Side effects are possible, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING

Beijing, China
Henan Provincial Cancer Hospital
RECRUITING

Zhengzhou, China
Henan Provincial People's Hospital
RECRUITING

Zhengzhou, China
Peking Union Medical College Hospital
WITHDRAWN

Beijing, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITING

Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.